The core business of Sudarshan Pharma Industries is to produce specialty chemicals and ingredients for pharma, agrochemicals, coating, paints, adhesives and several other industries.
Incorporated in 2008, SPIL supplies 50-plus pharma formulations under their brand name, including tablets, ointments, and injectables.
SPIL is involved in contract manufacturing, outsourcing and supplying generic pharma formulations and medicines to healthcare institutions, governments, NGOs, and hospitals.
Sudarshan Pharma Industries Ltd. IPO Objective
The IPO funds are primarily required to be spent on meeting working capital requirements and general corporate purposes.
Why should you invest in Sudarshan Pharma Industries Ltd. IPO?
Here are your top three reasons to consider investing in the IPO:
- They offer a diverse product portfolio, including specialty chemicals, bulk drugs, API, and pharmaceutical formulations.
- Their major international clients come from Taiwan, Oman, Uzbekistan, Bangladesh, UK and others.
- The company is expanding with a state-of-the-art manufacturing facility and expansion of distributor networks and logistic facilities in the five Indian states it covers.
Sudarshan Pharma Industries Ltd. Noteworthy highlights
- Their portfolio includes 2000 plus products in speciality chemicals, Intermediates for pharma, agrochemicals, paints, adhesives and other industrial chemicals.
- The company is exploring new markets with new products in Africa, South-East Asia, and the MENA region.
Sudarshan Pharma Industries Company Financials
| Parameters | Period Ending on September 30, 2022 (₹ Lakhs) | Year ending on 31st March, 2022 (₹ Lakhs) |
|---|---|---|
| Revenue from operation | 19,589.87 | 35,709.46 |
| Profit After Tax | 360.70 | 530.37 |
| EBITDA | NA | 1,143.57 |
| EBITDA Margin | NA | NA |
| EPS (Basic) | NA | 3.43 |
| Period Ended | Year ending on As on 31st March, 2022 | Year ending on As on 31st March, 2021 |
| Current Asset | 12,958.00 | 8,764.35 |
| Current Liabilities | 10,104.01 | 7,122.17 |
Know before investing
Strengths
3Experienced promoters with 25 years plus experience in the market.
They have developed the skills and expertise in innovation in producing speciality chemicals, pharma formulations, medicines etc.
They have ultra-modern facilities for all types of manufacturing activities.
Risks
3SPIL made a failed attempt to launch an IPO in 2019. It is its second attempt to gain investors’ favour.
The enthusiasm surrounding pharma stocks is fizzing out. In such a case it could be a risk-risk but low-return offer.
There are legal proceedings pending against the company’s promoters and subsidiaries.
